News & Updates

Real Endpoints Recent Developments

SCORING VALUE: New Tools Challenge Pharma’s US Pricing Bonanza

Posted by Julie Eagle on Monday, October 26, 2015

Tools that provide comparative information about the efficacy, drawbacks and costs of range of treatment options are helping payers, clinicians and — potentially — patients choose drugs wisely. Drug companies too can use them to design payer-friendly trials and credibly demonstrate differential value to payers.

Learn More

Too many cooks in the kitchen: Doctors need more time for patients and less time with reps

Posted by Julie Eagle on Monday, October 12, 2015

When did it become necessary to read a diagram to understand who to speak with at a pharma company? Pharmaceutical companies’ desire for specialization has transformed their customer-facing representatives into a large team of subject matter experts—when in reality, physicians are asking for a “Jack of all trades”.

Learn More

Overvaluing Speed To Market

Posted by Ryan Reid on Tuesday, August 25, 2015

The market bubble in Priority Review vouchers signals the dramatic overvaluation of getting to market first — and the relative undervaluation of the best-value product.

Learn More

The Shrinking Value of Best-In-Class & First-In-Class Drugs

Posted by Roger Longman on Friday, July 24, 2015

Incumbency ain’t worth what it once was. Pharma companies are spending billions to create advantages that won’t have significant lasting power. Smart followers can do as well – for less.

Learn More

The Specialty Drug Price Debate: Should Medtech Be Worried?

Posted by Julie Eagle on Thursday, July 16, 2015

As prices for specialty drugs like oncologics soar, outrage is mounting over the cost of the new therapies. Could any of this spill over to medical devices?

Learn More

New anti-cholesterol drugs could be biggest sellers ever…how do they measure up?

Posted by Julie Eagle on Wednesday, July 8, 2015

According to Real Endpoints’ (RE) just-released RxScorecard™ analysis of the new lipid-lowering therapies, the innovative PCSK9 inhibitors which could be highly valuable for patients with difficult-to-lower, high LDL-C (bad cholesterol) levels, are both comparable to each other and lack key data that would justify broader use.

Learn More